Dabigatran etexilate, also known as BIBR 1048MS, is a direct thrombin inhibitor. Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances. It appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.
Devarasetty, Sitaramaiah; Janni, Ravi; Nunna, Rambabu; Suraparaju, Raghu Ram. An improved process for the preparation of Dabigatran Etexilate mesylate and synthesis of its impurities. Pharma Chemica. Volume 10. Issue 4. Pages 127-148. Journal; Online Computer File. (2018).
Anon. Novel impurities of intermediates of ethyl 3-{[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}-phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl](2-pyridinyl)-amino}propanoate and its mesylate salt. IP.com Journal. Volume 13. Issue 12B. Pages 1-8. Journal; Patent. (2013).
Cheng, Qingfang; Wang, Qifa; Lu, Wei; Huang, Fenfen; Qin, Yajuan. Synthesis of dabigatran etexilate mesylate. Zhongguo Xinyao Zazhi. Volume 21. Issue 1. Pages 88-91. Journal. (2012).
De Zani, Daniele; Ferrari, Massimo; Valentincic, Maurizio. Process of preparing dabigatran etexilate mesylate and its intermediates and novel polymorph of dabigatran etexilate. Assignee Erregierre S.p.A., Italy. IT 1422626. (2016).
